PAGE Therapeutics, a biotech company focused on tackling metastatic cancer spread at its root, is pleased to announce the ...

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

A recent study by a team from Chiba University has demonstrated a promising approach for fighting antibiotic resistance by identifying a compound, V-161, that inhibits a sodium-pumping enzyme critical ...

In the next step, the researchers want to develop new molecules based on digoxin that are even better at dissolving the CTC clusters.

Dr Peter Verheyen explores quantum bits and consciousness, focusing this time on biochemical information processing ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

PAGE Therapeutics, a biotech company focused on tackling metastatic cancer spread at its root, is pleased to announce the publication of the results ...

PAGE Therapeutics, a biotech company focused on tackling metastatic cancer spread at its root, is pleased to announce the publication of the results of a clinical study conducted by Prof. Nicola Aceto ...

They found that when the animals' fat cells began overproducing GIPR, they had increased activity in sarco/endoplasmic reticulum calcium ATPase (SERCA) pathways, processes that use energy to ...

a Phase 1 Polθ ATPase inhibitor; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.